Evidence map›Paper›PMID 34937032›Full record

ArticleRespiration; international review of thoracic diseases2022

Late-Onset, Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Cohort Study of Long-Term Survivors.

Ole Henrik Myrdal, Trond Mogens Aaløkken, Phoi Phoi Diep, Ellen Ruud, Lorentz Brinch, Kristian Fosså, Henrik Mangseth, Johny Kongerud, Liv Ingunn Sikkeland, May B Lund

Open access · hybridAbstract read
In one paragraph

Article in Respiration; international review of thoracic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ole Henrik MyrdalDepartment of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Trond Mogens AaløkkenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Phoi Phoi DiepInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Ellen RuudInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Lorentz BrinchDepartment of Haematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Kristian FossåInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Henrik MangsethDepartment of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Johny KongerudDepartment of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Liv Ingunn SikkelandDepartment of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
May B LundDepartment of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Oslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at risk for pulmonary adverse events. Data on late-onset noninfectious pulmonary complications in long-term adult survivors of allo-HSCT are limited and incomplete.

objectivesThis study aimed (1) to determine occurrence and degree of pulmonary sequelae in adult survivors of allo-HSCT and (2) to identify associations between pulmonary function, high-resolution CT (HRCT), and clinical characteristics.

methodIn a nationwide, single-center cross-sectional study, 103 survivors (aged median [range] 35 [17-58] years, 53% females) were examined 17 (6-32) years after allo-HSCT and compared with healthy controls (n = 105). Methods included pulmonary function tests and HRCT.

resultsChronic graft-versus-host disease was diagnosed in 33% of survivors, including 12% with bronchiolitis obliterans syndrome (BOS). Mean lung volumes (TLC, FVC, and FEV1) and gas diffusing capacity were >80% of predicted for the survivors as a group, but significantly lower than in healthy controls. Pathological HRCT findings were detected in 48% of the survivors (71% airways disease, 35% interstitial lung disease, and 24% apical subpleural interstitial thickening). Air trapping (%) on HRCT correlated with % predicted FEV1, p < 0.001. In a multiple logistic regression model, both BOS and pathological findings on HRCT were associated with chemotherapy prior to allo-HSCT, p < 0.05.

conclusionsLong-term allo-HSCT survivors had significantly lower pulmonary function than age- and gender-matched healthy controls and nearly half had pathological findings on HRCT. Longitudinal data will determine if pulmonary sequelae will remain stable or progress. We recommend lifelong monitoring of pulmonary function in allo-HSCT survivors. HRCT provides additional information, but is not suited for surveillance.

Indexed as

Bronchiolitis ObliteransHematopoietic Stem Cell TransplantationAdultAgedCohort StudiesCross-Sectional StudiesDisease ProgressionFemaleHumansMaleSurvivorsAllogeneic hematopoietic stem cell transplantationBronchiolitis obliterans syndromeHigh-resolution CTLong-term follow-upPulmonary function

Identifiers

PMID34937032
PMCPMC9248297
OpenAlexW4200396192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.